Nomogram based on monocyte-to-lymphocyte ratio to predict survival of unresectable esophageal squamous cell carcinoma who receive first-line pd-1/pd-l1 inhibitors combined with chemotherapy

HIGHLIGHTS

• who: Xiaolu Ma and collaborators from the Department of Medical Oncology, The Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China have published the research work: Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy, in the Journal: (JOURNAL) of 10/Oct/2022
• what: This study assessed whether NLR or MLR could be a reliable predictor of survival for treatment-naive locally advanced or metastatic ESCC patients who had received PD1/PD-L1 antibodies combined with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.